Surrey Heartlands

Joint Formulary & PAD

Hydroxycarbamide - Sickle-cell disease

You are here : Home > Formulary Search > Hydroxycarbamide - Sickle-cell disease

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Blue
Formulations :
  • Capsules
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
BNF SPC
Un
Restrictions / Comments :
Important

Off-label use in Sickle Cell. Initiation and stabilisation (3 months) by the specialist team before any request for primary care prescribing.

 

Status 2

Red
Formulations :
  • Oral solution
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
BNF SPC
Un
Restrictions / Comments :
Important

Sickle Cell in paediatrics - on advice from tertiary centre.

 

Status 3

Non Formulary
Formulations :
  • Tablets
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
BNF SPC
NFD1
Restrictions / Comments :
Important

Tablets are considerably more expensive than capsules which have been agreed for off-label use in Sickle Cell.

Documentation

  • No records returned.

PAD Profile

ChemicalSubstance :
Hydroxycarbamide
Indication :
Sickle-cell disease
Group Name :
Keywords :
Brand Names Include :
Siklos, Xromi
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
0
Traffic Light Entries :
3

Other Indications

Below are listed other indications that Hydroxycarbamide is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Sickle-cell disease.

  • No records returned.

Committee Recommendations (1)

04 Dec 09 - Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
Siklos is a new hydroxycarbamide preparation, the first to obtain a specific license for sickle cell crisis. However, in light of it costing ten times that of the generic equivalents the committee recommneded that this product is not used and the generic to be used off license. This decision is supported by the London Specialised Commission Group and information received from the London & South East Medicines Information Service.